Noxopharm Limited Stock: price and insider trades · Australia
Noxopharm Limited: what insiders have been doing
Noxopharm Limited has a thin disclosure history in our data (latest filing: 1 June 2026). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by ASX. They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2024FY ended June 2024 · cache
A$0.05
Analyst consensus
Income statement
EBITDA-A$3.5M
Net income-A$3.6M0.0% margin
Valuation
Beta0.13
Balance sheet & cash
Market capA$15.4M
Total debtA$160.6k
Free Cash Flow-A$684.3k
Profitability & ownership
ROE-343.6%
ROA-66.6%
% insiders31.8%
% institutions0.0%
Last declaration on 1 June 2026
Declarations1 total
- ●Executives37,800 AUD0ASX
1 of 1 declaration
About Noxopharm Limited
Noxopharm Limited is a biopharmaceutical company focused on developing treatments for cancer and other serious diseases. It is listed on the XASX market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
